Market Overview

SciFluor Announces Appointment of Robert Dempsey to Board of Directors

Share:

-- Dempsey brings deep knowledge of the Pharmaceutical Industry and
Ophthalmology commercial experience to the Board of Directors --

SciFluor
Life Sciences, Inc.
today announced that Robert Dempsey, MBA, has
joined the Board of Directors. Robert will bring his extensive knowledge
of the pharmaceutical industry along with 25 years focused in
ophthalmology to the Board of SciFluor.

Robert Dempsey has been instrumental in building and launching
franchises and has extensive leadership experience in sales, marketing,
medical affairs and business development at major eye care organizations
including Shire, where he is currently leading the Global Ophthalmology
Franchise, and at Bausch + Lomb, Inspire and Allergan. Mr. Dempsey is
recognized for his knowledge and global experience in ophthalmology, and
his strategic relationships with industry leaders and professionals in
eye care. He is based in Boston, Massachusetts and holds a Master's in
Business Administration and a Bachelor of Science from Northeastern
University.

"We are delighted that Bob has agreed to join the Board of SciFluor,"
commented William Koster, PhD, Chairman of the Board for SciFluor. "His
industry experience, commercial expertise and contacts will be a great
addition to the team as we drive forward with multiple programs in
clinical development. In particular, Bob's in-depth knowledge of the
ophthalmology field will provide exceptional value to SciFluor's lead
Phase 2 program with SF0166, a topical drug designed to treat diseases
of the retina."

About SciFluor Life Sciences, Inc.

SciFluor creates proprietary best-in-class drugs based on
well-understood pathways in areas of significant medical need such as
ophthalmology, neuroscience and fibrotic diseases. Our lead clinical
drug candidate, SF0166, is an eye drop therapeutic for treating
back-of-the-eye diseases. www.scifluor.com.

View Comments and Join the Discussion!